Sage Rhino Capital LLC Makes New $213,000 Investment in Cencora, Inc. $COR

Sage Rhino Capital LLC acquired a new stake in Cencora, Inc. (NYSE:COR) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 712 shares of the company’s stock, valued at approximately $213,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in COR. Net Worth Advisory Group boosted its holdings in Cencora by 1.4% during the first quarter. Net Worth Advisory Group now owns 2,645 shares of the company’s stock valued at $736,000 after purchasing an additional 36 shares in the last quarter. Obermeyer Wealth Partners boosted its stake in Cencora by 1.3% in the 1st quarter. Obermeyer Wealth Partners now owns 2,724 shares of the company’s stock valued at $758,000 after buying an additional 36 shares in the last quarter. Grove Bank & Trust grew its position in Cencora by 4.3% in the second quarter. Grove Bank & Trust now owns 879 shares of the company’s stock valued at $264,000 after acquiring an additional 36 shares during the period. U.S. Capital Wealth Advisors LLC raised its stake in Cencora by 0.4% during the second quarter. U.S. Capital Wealth Advisors LLC now owns 8,547 shares of the company’s stock worth $2,563,000 after acquiring an additional 38 shares in the last quarter. Finally, Cromwell Holdings LLC boosted its stake in shares of Cencora by 9.5% in the 1st quarter. Cromwell Holdings LLC now owns 450 shares of the company’s stock valued at $125,000 after purchasing an additional 39 shares in the last quarter. 97.52% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on COR shares. Wells Fargo & Company lifted their price target on shares of Cencora from $337.00 to $354.00 and gave the company an “overweight” rating in a report on Wednesday, August 13th. Morgan Stanley set a $330.00 target price on Cencora and gave the stock an “equal weight” rating in a report on Wednesday, July 16th. Finally, Jefferies Financial Group increased their price target on Cencora from $275.00 to $300.00 and gave the stock a “hold” rating in a research report on Monday, June 30th. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Cencora has a consensus rating of “Moderate Buy” and an average price target of $311.25.

Insider Buying and Selling at Cencora

In other Cencora news, CEO Robert P. Mauch sold 5,097 shares of the business’s stock in a transaction dated Thursday, September 18th. The stock was sold at an average price of $290.00, for a total value of $1,478,130.00. Following the completion of the transaction, the chief executive officer directly owned 39,274 shares of the company’s stock, valued at approximately $11,389,460. The trade was a 11.49% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total value of $9,087,111.00. Following the sale, the chairman directly owned 305,913 shares of the company’s stock, valued at approximately $88,671,942.18. The trade was a 9.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 55,993 shares of company stock worth $16,292,923 in the last ninety days. 10.80% of the stock is currently owned by company insiders.

Cencora Trading Up 2.7%

Shares of NYSE COR opened at $306.94 on Monday. The company’s 50 day simple moving average is $293.00 and its 200 day simple moving average is $288.82. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53. The firm has a market capitalization of $59.51 billion, a P/E ratio of 31.58, a P/E/G ratio of 1.56 and a beta of 0.62. Cencora, Inc. has a fifty-two week low of $218.65 and a fifty-two week high of $310.00.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, August 6th. The company reported $4.00 EPS for the quarter, beating analysts’ consensus estimates of $3.79 by $0.21. The business had revenue of $80.66 billion during the quarter, compared to the consensus estimate of $80.34 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The firm’s revenue was up 8.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.34 earnings per share. On average, analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Friday, August 15th were paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend was Friday, August 15th. Cencora’s dividend payout ratio (DPR) is presently 22.63%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.